Table 4.
Evolution over time in 20 year survivors of renal function and liver function, arterial hypertension, diabetes mellitus, dyslipidemia, and immunosuppression (n = 28)
| 1st year | 5th year | 10th year | 15th year | 20th year | |
|---|---|---|---|---|---|
| Liver function | |||||
| AST (IU/L) | 28 (10–178) | 36 (14–160) | 39 (13–133) | 32 (14–66) | 33 (13–135) |
| ALT (IU/L) | 38 (12–370) | 53 (10–297) | 41 (13–205) | 41 (11–111) | 27 (11–152) |
| Total bilirubin (mg/dL) | 0.9 (0.3–2.5) | 0.7 (0.3–2.2) | 0.7 (0.4–1.7) | 0.7 (0.3–2) | 0.6 (0.3–1.1) |
| Renal function | |||||
| (eGFR mL/min/1.73 m2) | 60 (18–96) | 60 (21–112) | 67 (12–89) | 57 (12–98) | 64 (6–144) |
| Arterial hypertension | 12 (43 %) | 15 (54 %) | 18 (64 %) | 17 (61 %) | 17 (61 %) |
| Diabetes mellitus | 4 (14 %) | 4 (14 %) | 6 (21 %) | 6 (21 %) | 6 (21 %) |
| Dyslipidemia | 6 (21 %) | 7 (25 %) | 12 (43 %) | 12 (43 %) | 12 (43 %) |
| Immunosuppression | |||||
| CyA | – | 14 (50 %) | 13 (46 %) | 11 (39 %) | 11 (39 %) |
| Tac | 4 (14 %) | 7 (25 %) | 7 (25 %) | 5 (18 %) | 4 (14 %) |
| CyA + St/MMF | 21 (75 %) | 6 (21 %) | 1 (4 %) | 3 (11 %) | 3 (11 %) |
| Tac + St/MMF | 3 (11 %) | – | 3 (11 %) | 6 (21 %) | 6 (21 %) |
| Others | – | 1 (4 %) | 2 (7 %) | – | 1 (4 %) |
| Withdrawal | – | – | 2 (7 %) | 3 (11 %) | 3 (11 %) |
AST aspartate transaminase, ALT alanine transaminase, eGFR estimated glomerular filtration rate, CyA cyclosporine, St steroids, Tac tacrolimus, MMF mycophenolate mofetil